Actinium Pharmaceuticals
ATNM
27 hedge funds and large institutions have $5.65M invested in Actinium Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 3 closing their positions.
500% more call options, than puts
Call options by funds: $48K | Put options by funds: $8K
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
12% more capital invested
Capital invested by funds: $5.02M → $5.65M (+$626K)
0.12% less ownership
Funds ownership: 0.34% → 0.22% (-0.12%)
10% less funds holding
Funds holding: 30 → 27 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$898K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$588K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$55.8K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
+$36.3K |
| 5 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$20.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sio Capital Management
New York
|
-$1.44M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$760K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$41.7K |
| 4 |
Renaissance Technologies
New York
|
-$27.1K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$26.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of Montreal
Toronto,
Ontario, Canada
| $4K | – | – | – |
|
27
Creative Planning
Overland Park,
Kansas
| $4K | +$2.07K | +54 | +200% |
|
|
SCM
28
Sio Capital Management
New York
| – | -$1.44M | -54,969 | Closed |
|
|
SM
29
Sabby Management
Miami Beach,
Florida
| – | -$760K | -28,954 | Closed |
|
|
30
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$41.7K | -1,086 | Closed |
|
ATNM Hedge Fund Activity: Q1 2017 in Review
27 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q1 2017, worth a combined $5.65M — up 12% from $5.02M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ATNM positions and 3 closed out — a net gain of 1 holder — while 8 added to existing stakes and 5 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $898K. The largest seller was Sio Capital Management, exiting entirely with an estimated $1.44M sold.
- 27 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q1 2017, down from 30 in Q4 2016.
- Funds reported $5.65M of Actinium Pharmaceuticals stock for Q1 2017, up 12% quarter-over-quarter.
- 4 funds opened new Actinium Pharmaceuticals positions in Q1 2017 and 3 closed out, a net change of +1 holder.
- The largest Actinium Pharmaceuticals buyer in Q1 2017 was BlackRock, an estimated $898K added.
- The largest Actinium Pharmaceuticals seller in Q1 2017 was Sio Capital Management, an estimated $1.44M sold.
Based on aggregated 13F filings for Q1 2017.